| Recruiting | A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutane NCT07391670 | AstraZeneca | Phase 1 |
| Recruiting | Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metas NCT07446855 | AstraZeneca | Phase 1 / Phase 2 |
| Recruiting | A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out W NCT07224425 | Boehringer Ingelheim | Phase 1 |
| Recruiting | A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors NCT07165067 | AP Biosciences Inc. | Phase 1 |
| Recruiting | Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis NCT07403370 | Shandong Cancer Hospital and Institute | — |
| Recruiting | A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors NCT07160725 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study to Evaluate the Safety and Tolerability of EP0089 NCT07030478 | Ellipses Pharma | Phase 1 / Phase 2 |
| Recruiting | A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumour NCT06815575 | Race Oncology Ltd | Phase 1 |
| Recruiting | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors NCT06789172 | Epkin | Phase 1 |
| Active Not Recruiting | Reintegrating a Systematic Review Consultation With the General Practitioner After the Cancer Diagnosis Has Be NCT06589414 | Institut Claudius Regaud | N/A |
| Active Not Recruiting | A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous NCT06619509 | Boehringer Ingelheim | Phase 2 |
| Recruiting | Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alteratio NCT06581432 | Boehringer Ingelheim | Phase 2 |
| Recruiting | A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours NCT06725758 | Orion Corporation, Orion Pharma | Phase 1 / Phase 2 |
| Recruiting | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Canc NCT05770102 | Cancer Research UK | Phase 2 / Phase 3 |
| Completed | Phase I Clinical Trial of BH002 in Patients With Advanced Solid Tumors NCT06231277 | Zhuhai Beihai Biotech Co., Ltd | Phase 1 |
| Completed | A Bioequivalence Study of Docetaxel Injection in Patients With Solid Tumours NCT04889599 | Zhuhai Beihai Biotech Co., Ltd | Phase 3 |
| Recruiting | A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test NCT04529122 | Hoffmann-La Roche | — |
| Completed | Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours NCT04236414 | AstraZeneca | Phase 1 |
| Completed | A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When NCT04179071 | AstraZeneca | Phase 1 |
| Unknown | Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours NCT03415100 | The Third Affiliated Hospital of Guangzhou Medical University | Phase 1 |
| Completed | Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advance NCT03333824 | AstraZeneca | Phase 1 |
| Withdrawn | A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical NCT03266159 | GlaxoSmithKline | Phase 2 |
| Completed | Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours NCT03315091 | AstraZeneca | Phase 1 |
| Terminated | Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Part NCT03150056 | GlaxoSmithKline | Phase 1 |
| Completed | Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairm NCT02923947 | AstraZeneca | Phase 1 |
| Terminated | A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR NCT02687386 | Dr David Ziegler | Phase 1 |
| Terminated | TOP-TRIAL Safety of Not Flushing Non-used PORT-A-CATH® in Cancer Patients NCT02492477 | Krankenhaus Barmherzige Schwestern Linz | Phase 1 |
| Completed | Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CN NCT02343718 | Canadian Cancer Trials Group | Phase 1 |
| Unknown | An Extension Study of LON002 in Patients With Cancer NCT02390986 | LondonPharma Ltd. | N/A |
| Completed | Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Live NCT02161770 | AstraZeneca | Phase 1 |
| Completed | Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors NCT01956669 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours NCT02215850 | Welichem Biotech Inc. | Phase 1 |
| Unknown | A Phase 1/2a Study of LON002 in Subjects With Advanced Solid Tumours NCT02263950 | LondonPharma Ltd. | Phase 1 / Phase 2 |
| Completed | Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours NCT02264418 | Orion Corporation, Orion Pharma | Phase 1 |
| Completed | To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and The NCT02093351 | AstraZeneca | Phase 1 |
| Completed | To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Vo NCT02093728 | AstraZeneca | Phase 1 |
| Completed | Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liv NCT01894243 | AstraZeneca | Phase 1 |
| Completed | To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interva NCT02056392 | AstraZeneca | Phase 1 |
| Completed | To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy NCT02063204 | AstraZeneca | Phase 1 |
| Completed | To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers NCT02046850 | AstraZeneca | Phase 1 |
| Completed | Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With NCT01929603 | AstraZeneca | Phase 1 |
| Completed | Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or NCT01894256 | AstraZeneca | Phase 1 |
| Completed | To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in He NCT01974349 | AstraZeneca | Phase 1 |
| Completed | To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect NCT01900028 | AstraZeneca | Phase 1 |
| Completed | Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in NCT01931761 | AstraZeneca | Phase 1 |
| Completed | To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval NCT01921140 | AstraZeneca | Phase 1 |
| Completed | Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly NCT02360345 | Royal Marsden NHS Foundation Trust | Phase 1 |
| Recruiting | Tissue Collection Framework To Improve Outcomes In Solid Tumours NCT03572192 | Queen Mary University of London | — |
| Completed | Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced NCT01928940 | GlaxoSmithKline | Phase 2 |
| Terminated | Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alteratio NCT01948297 | Debiopharm International SA | Phase 1 |
| Completed | D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours NCT01851265 | AstraZeneca | Phase 1 |
| Completed | Phase I Trial of VS-6766 Alone and in Combination With Everolimus NCT02407509 | Royal Marsden NHS Foundation Trust | Phase 1 |
| Completed | Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or NCT01767454 | GlaxoSmithKline | Phase 1 |
| Completed | Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics P NCT01998607 | Amgen | — |
| Completed | Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors NCT01324258 | GlaxoSmithKline | Phase 1 |
| Completed | Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematolog NCT01626547 | Hospira, now a wholly owned subsidiary of Pfizer | — |
| Completed | A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia NCT01184274 | NCIC Clinical Trials Group | Phase 1 |
| Completed | An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the NCT01266954 | GlaxoSmithKline | Phase 1 |
| Completed | Dose-Escalation Study of GSK2126458 NCT00972686 | GlaxoSmithKline | Phase 1 |
| Completed | Utility and Work Productivity Data for Economic Evaluation of Breast Cancer Therapies in the Netherlands and S NCT01209091 | GlaxoSmithKline | — |
| Completed | Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors NCT00732420 | GlaxoSmithKline | Phase 1 |
| Completed | A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors NCT00742261 | GlaxoSmithKline | Phase 1 |
| Completed | Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumo NCT00687622 | GlaxoSmithKline | Phase 1 |
| Terminated | Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma NCT00695448 | GlaxoSmithKline | Phase 1 |
| Completed | A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function NCT00483860 | GlaxoSmithKline | Phase 1 |
| Completed | A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally NCT00743067 | GlaxoSmithKline | Phase 1 |
| Terminated | AZD1152 in Patients With Advanced Solid Malignancies-Study 3 NCT00497679 | AstraZeneca | Phase 1 |
| Completed | A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally NCT00742131 | GlaxoSmithKline | Phase 1 |
| Completed | Ispinesib In Combination With Carboplatin In Patients With Solid Tumors NCT00136578 | GlaxoSmithKline | Phase 1 |
| No Longer Available | Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma NCT03702036 | GlaxoSmithKline | — |